SPX4,180.94+35.75 0.86%
DIA330.72+2.75 0.84%
IXIC12,833.76+176.21 1.39%

--Benchmark Capital Adjusts Price Target on Amedisys to $165 From $175, Maintains Buy Rating

--Benchmark Capital Adjusts Price Target on Amedisys to $165 From $175, Maintains Buy Rating

MT Newswires · 07/28/2022 08:18

Please log in to view news